These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

74 related items for PubMed ID: 12211413

  • 1. Vitronectin receptors in vascular disorders.
    Mousa SA.
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1191-5. PubMed ID: 12211413
    [Abstract] [Full Text] [Related]

  • 2. alphav Vitronectin receptors in vascular-mediated disorders.
    Mousa SA.
    Med Res Rev; 2003 Mar; 23(2):190-9. PubMed ID: 12500288
    [Abstract] [Full Text] [Related]

  • 3. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
    Wilkinson-Berka JL, Jones D, Taylor G, Jaworski K, Kelly DJ, Ludbrook SB, Willette RN, Kumar S, Gilbert RE.
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
    [Abstract] [Full Text] [Related]

  • 4. Alpha(v)beta(3) integrin in angiogenesis and restenosis.
    Kerr JS, Mousa SA, Slee AM.
    Drug News Perspect; 2001 Apr; 14(3):143-50. PubMed ID: 12819820
    [Abstract] [Full Text] [Related]

  • 5. Expression of alphav, alpha4, alpha5 and beta3 integrin subunits, fibronectin and vitronectin in goat peri-implantation.
    García P, Nieto A, Sánchez MA, Pizarro M, Flores JM.
    Anim Reprod Sci; 2004 Jan; 80(1-2):91-100. PubMed ID: 15036518
    [Abstract] [Full Text] [Related]

  • 6. Fibrinogen interaction of CHO cells expressing chimeric alphaIIb/alphavbeta3 integrin.
    Chen JJ, Su XY, Xi XD, Lin LP, Ding J, Lu H.
    Acta Pharmacol Sin; 2008 Feb; 29(2):204-10. PubMed ID: 18215349
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Heterophilic interactions between cell adhesion molecule L1 and alphavbeta3-integrin induce HUVEC process extension in vitro and angiogenesis in vivo.
    Hall H, Djonov V, Ehrbar M, Hoechli M, Hubbell JA.
    Angiogenesis; 2004 Feb; 7(3):213-23. PubMed ID: 15609076
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 1: design and synthesis of a lead compound exhibiting alpha(v)beta3/alpha(IIb)beta3 dual antagonistic activity.
    Kubota D, Ishikawa M, Yamamoto M, Murakami S, Hachisu M, Katano K, Ajito K.
    Bioorg Med Chem; 2006 Apr 01; 14(7):2089-108. PubMed ID: 16309911
    [Abstract] [Full Text] [Related]

  • 14. Microglial expression of alphavbeta3 and alphavbeta5 integrins is regulated by cytokines and the extracellular matrix: beta5 integrin null microglia show no defects in adhesion or MMP-9 expression on vitronectin.
    Milner R.
    Glia; 2009 May 01; 57(7):714-23. PubMed ID: 18985734
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling.
    Shen MR, Hsu YM, Hsu KF, Chen YF, Tang MJ, Chou CY.
    Carcinogenesis; 2006 May 01; 27(5):962-71. PubMed ID: 16400188
    [Abstract] [Full Text] [Related]

  • 17. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.
    Ishikawa M, Kubota D, Yamamoto M, Kuroda C, Iguchi M, Koyanagi A, Murakami S, Ajito K.
    Bioorg Med Chem; 2006 Apr 01; 14(7):2109-30. PubMed ID: 16309912
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Alpha v integrin affinity/specificity and antiangiogenesis effect of a novel tetraaza cyclic peptide derivative, SU015, in various species.
    Mousa SA.
    J Cardiovasc Pharmacol; 2005 May 01; 45(5):462-7. PubMed ID: 15821442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.